CRSP Earnings Beat

CRISPR Therapeutics (CRSP) reported impressive Q4 2024 earnings today, beating analyst estimates. The company posted earnings of -$0.44 per share, surpassing the consensus estimate of -$1.15 by $0.71. This significant beat demonstrates the company's strong financial performance and operational efficiency.

Key highlights from the earnings report include:

• Revenue of $35.7 million for Q4 2024
• R&D expenses decreased to $82.2 million from $95.1 million in Q4 2023
• Strong cash position with $1.9 billion in cash and equivalents as of December 31, 2024

The company's CASGEVY® treatment continues to gain momentum, with over 50 authorized treatment centers activated globally and more than 50 patients having cells collected across all regions by the end of 2024.CRISPR Therapeutics is poised for a catalyst-rich 2025, with several key updates expected across its pipeline, including:

• Updates on lead in vivo cardiovascular programs in the first half of 2025
• A broad update on CTX112 in oncology and autoimmune diseases in mid-2025
• Ongoing clinical trials for next-generation CAR T products CTX112™ and CTX131™
• Progress on in vivo gene editing candidates CTX310™ and CTX320™

Despite the earnings beat, CRISPR Therapeutics traded up only slightly, reaching $39.62 on Tuesday and broke 40 in after-hours trading.